


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| | | | | | |
|-------|---|----|---|------------------------|-------------------|
| Sheet | 1 | of | 1 | Attorney Docket Number | 20555/1203301-US3 |
|-------|---|----|---|------------------------|-------------------|

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| KAB | 1 | 4,741,901 B1 | 05-03-1988 | Levinson et al. | |
| | 2 | 5,593,846 B1 | 01-14-1997 | Schenk et al. | |
| | 3 | 5,604,102 B1 | 02-18-1997 | McConlogue et al. | |
| | 4 | 5,786,180 B1 | 07-28-1998 | Konig et al. | |
| | 5 | 5,851,996 B1 | 12-22-1998 | Kline | |
| | 6 | 6,287,793 B1 | 09-11-2001 | Schenk et al. | |
| | 7 | 6,610,493 B1 | 08-26-2003 | Citron et al. | |
| | 8 | 6,710,226 B1 | 03-23-2004 | Schenk | |
| | 9 | 6,717,031 B2 | 04-06-2004 | Games et al. | |
| | 10 | 6,743,427 B1 | 06-01-2004 | Schenk | |
| | 11 | 6,761,888 B1 | 07-13-2004 | Schenk | |
| | 12 | 6,787,523 B1 | 09-07-2004 | Schenk | |
| | 13 | 6,905,686 B1 | 06-14-2005 | Schenk | |
| ↓ | 14 | 6,913,745 B1 | 07-05-2005 | Schenk | |
| KAB | 15 | 6,923,964 B1 | 08-02-2005 | Schenk | |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | |
| KAB | 16 | WO 96/25435 A1 | 08-22-1996 | Konig et al. | T ⁶ |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|-----------------------|---|--|--|--|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | | | |
| KAB | 17 | Duenas et al, <i>Bio Techniques</i> , 16(3):476-482 (1994) | | | |
| | 18 | Goding, <i>Monoclonal Antibodies</i> , Academic Press Inc., London, pp. 56-97 (1983) | | | |
| | 19 | Jarrett et al., "The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease," <i>Biochemistry</i> 32:4693-4697 (1993). | | | |
| | 20 | Quitschke et al., "The initiator element and proximal upstream sequences affect transcriptional activity and start site selection in the amyloid β -protein precursor promoter," <i>J. Biol. Chem.</i> 271(36), pp. 22231-22239 (1996) | | | |
| | 21 | Saldo et al., "Autolytic transition of μ -calpain upon activation as resolved by antibodies distinguishing between the pre- and post-autolysis forms," <i>J. Biochem.</i> 111:81-86 (1992). | | | |
| ↓ | 22 | Saldo et al., "In situ capture of mu-calpain activation in platelets," <i>J. Biol. Chem.</i> 268(10): (1993) (Abstract Only) | | | |
| KAB | 23 | Saldo et al., "Spatial resolution of the primary β -amyloidogenic process induced in postischemic hippocampus," <i>J. Biol. Chem.</i> 269(21):15253-15257 (1994). | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

| | | |
|-------------------------|-----------------|---------|
| <i>Kimberly Ballard</i> | Date Considered | 2/22/06 |
|-------------------------|-----------------|---------|